The Performance Accountability Council latest's report on “Trusted Workforce 2.0 said agencies have updated all major policies related to personnel vetting.
Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.